“Our trial shows that potentially actionable genomic alterations are common across a variety of tumor types and that significant clinical trial infrastructure needs to be built to optimally utilize genomic testing through trial enrollment,” says Funda Meric-Bernstam, MD, medical director at the Khalifa Institute for Personalized Cancer Therapy and chair of the department of investigational cancer therapeutics, both at The University of Texas MD Anderson Cancer Center (MDACC) in Houston.

中文翻译：

---

将患者纳入基因组匹配的临床试验发现具有挑战性

“我们的试验表明，潜在可操作的基因组改变在各种肿瘤类型中都很常见，需要建立重要的临床试验基础设施，以通过试验登记优化利用基因组检测，”Khalifa 医学主任 Funda Meric-Bernstam 医学博士说。德克萨斯大学 MD 安德森癌症中心 (MDACC) 的个性化癌症治疗研究所和研究性癌症治疗学系主任。